Inovio Pharmaceuticals Inc said on Monday it had completed Phase II enrolment for a mid-to-late stage US trial of its Covid-19 vaccine candidate and expects to report data early in the second quarter.Inovio said it was testing the impact of its vaccine candidate, IN0-4800, on new SARS-CoV-2 variants, as well as developing next-generation Covid-19 vaccine candidates that could be tailored to known and unknown SARS-CoV-2 variants."The pan-Covid candidate is designed to provide protection against the UK, South African and Brazilian stream as well as potentially the currently unknown SARS-CoV-2 variant," Inovio senior executive Kate Broderick said.The vaccine news did not boost Inovio shares, which were down 3% in extended trading.The company.